Business Description
![Ultragenyx Pharmaceutical Inc Ultragenyx Pharmaceutical Inc logo](https://static.gurufocus.com/logos/0C0000AIPM.png?14)
Ultragenyx Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US90400D1081
Compare
Compare
Traded in other countries / regions
RARE.USA0LIF.UKUP0.GermanyRARE.Mexico IPO Date
2018-01-25Description
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 20.39 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.8 | |||||
Beneish M-Score | -2.37 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.9 | |||||
3-Year EBITDA Growth Rate | -45.1 | |||||
3-Year EPS without NRI Growth Rate | -17.3 | |||||
3-Year FCF Growth Rate | -34.8 | |||||
3-Year Book Growth Rate | -42.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 27.12 | |||||
Future 3-5Y Total Revenue Growth Rate | 25.4 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 90.25 | |||||
9-Day RSI | 84.3 | |||||
14-Day RSI | 79.05 | |||||
6-1 Month Momentum % | -9.2 | |||||
12-1 Month Momentum % | 22.64 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.54 | |||||
Quick Ratio | 3.39 | |||||
Cash Ratio | 2.8 | |||||
Days Inventory | 200.73 | |||||
Days Sales Outstanding | 65.13 | |||||
Days Payable | 257.73 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.2 | |||||
Shareholder Yield % | -0.23 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.15 | |||||
Operating Margin % | -114.04 | |||||
Net Margin % | -121.57 | |||||
FCF Margin % | -102.32 | |||||
ROE % | -290 | |||||
ROA % | -42 | |||||
ROIC % | -75.33 | |||||
ROC (Joel Greenblatt) % | -175.01 | |||||
ROCE % | -45.87 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.58 | |||||
PB Ratio | 12.09 | |||||
Price-to-Tangible-Book | 23.51 | |||||
EV-to-EBIT | -8.66 | |||||
EV-to-EBITDA | -9.25 | |||||
EV-to-Revenue | 9.36 | |||||
EV-to-Forward-Revenue | 8.32 | |||||
EV-to-FCF | -9.15 | |||||
Earnings Yield (Greenblatt) % | -11.55 | |||||
FCF Yield % | -9.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ultragenyx Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 481.303 | ||
EPS (TTM) ($) | -7.3 | ||
Beta | -0.84 | ||
Volatility % | 41.04 | ||
14-Day RSI | 79.05 | ||
14-Day ATR ($) | 1.569058 | ||
20-Day SMA ($) | 50.677415 | ||
12-1 Month Momentum % | 22.64 | ||
52-Week Range ($) | 31.83 - 57.85 | ||
Shares Outstanding (Mil) | 92.17 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ultragenyx Pharmaceutical Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ultragenyx Pharmaceutical Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Ultragenyx Pharmaceutical Inc Frequently Asked Questions
What is Ultragenyx Pharmaceutical Inc(LTS:0LIF)'s stock price today?
The current price of LTS:0LIF is $57.14. The 52 week high of LTS:0LIF is $57.85 and 52 week low is $31.83.
When is next earnings date of Ultragenyx Pharmaceutical Inc(LTS:0LIF)?
The next earnings date of Ultragenyx Pharmaceutical Inc(LTS:0LIF) is 2024-11-01 Est..
Does Ultragenyx Pharmaceutical Inc(LTS:0LIF) pay dividends? If so, how much?
Ultragenyx Pharmaceutical Inc(LTS:0LIF) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |